Trial Profile
A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Formoterol (Primary) ; Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 07 Jun 2018 Status changed from recruiting to completed.
- 24 May 2018 Planned End Date changed from 5 Feb 2019 to 28 May 2018.
- 24 May 2018 Planned primary completion date changed from 31 May 2018 to 28 May 2018.